الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
Our study aimed at comparing the frequency of symptoms recurrence after treatment of overactive bladder with Solifenacin using gradual weaning versus sudden stopping of the drug.
Our study will include 60 patients that are recently diagnosed with idiopathic OAB, and not received any treatment for it. they will be treated by solifenacin 5 mg / twice daily for 4 weeks, then we will categorize the responders into 2 groups:
- group A: half of responders will stop treatment.
- group B: the other half of responders will take Solifenacin 5 mg for 2 weeks as the following manner:
* First week Solifenacin 5 mg once daily.
* Second week Solifenacin 5 mg every other day.
group A will be followed up after 1 and 3 months from stopping the drug, while group B will be followed up after 1 and 3 months from the end of gradual weaning by Patient Overactive bladder questionnaire.
Pregnant women, patients with severe hepatic dysfunction (eg. Hepatic Cirrhosis, Hepatic failure), diabetic patients, patients with UTIs, patients who have been treated either surgically or medically for OAB before, patients who have BOO ( BPH, and UB stones ), patients who are hypersensitive to Solifenacin, patients with neurogenic OAB, and patients who don’t respond to treatment of overactive bladder.
Our study shows that the majority of patients (80.0%) reported no symptoms recurrence after one month termination of treatment, and the remaining (20%) of patients reported feeling symptoms recurrence as follow:
group I with sudden stopping of the treatment showed higher incidence of symptoms recurrence (33.3%) while the recurrence in the group II with gradual weaning from the treatment was only (6.7%); (p-value=0.001)
This were in agreement with Chapple CR et al. 2005, C R Chapple et al. 2006, Basra RK et al.2008, Chapple CR et al. 2004, and Choo MS et al. 2005, but weren’t in agreement with Aram Kim et al. 2017.
Also our study showed the recurrence of symptoms after 3 months of discontinuation of treatment are 41.7% ( group I = 60% and group II = 23.3%), which were in agreement with Aram Kim et al. 2017, but weren’t in agreement with Lee YS et al.2011.
Duration of treatment in our study is one month which is sufficient to gain improvement of OAB symptoms, which were in agreement with Sheng-Mou Hsiao et al. 2015, Chapple CR et al. 2004, and Lee YS et al. 2011, but weren’t in agreement with Oelke M et al. 2013.
By comparing persons with or without OAB symptom recurrence, significant variation between two groups is found in form of higher recurrence among older patients 61.67 ±12.1 (SD) years; (p-value=0.001).
Also we found that incidence of recurrence was significantly higher by increasing the OABSS at the baseline level (before treatment) where the mean scores were 10.25 ±0.9 (SD) Points; (p-value=0.001).
While the gender of patients was not statistically related to the recurrence of symptoms; (p-value=0.325).
This were in agreement with Choo MS et al. 2005, Sheng-Mou Hsiao et al. 2015, and Hsiao SM et al. 2013, but weren’t in agreement with Lee YS et al. 2011, and Aram Kim et al. 2017.